Center for U.S. Policy

2

6

571

Center for U.S. Policy@USPolicyCenter·4 Şub

Last week, the FDA approved the first new pain reliever in 20+ years. This non-opioid targets sodium channels to treat acute pain. While trials showed its effectiveness in post-surgical patients, its benefits for chronic pain may be limited. Learn more: fda.gov/news-events/pr…

English

37

Center for U.S. Policy@USPolicyCenter·8 Tem

Tomorrow, our Chairman @MCBtweets will moderate a Congressional briefing on enhancing decision-making and patient outcomes with AI, featuring policymakers, physicians, tech innovators, and patient care advocates. RSVP here: forms.office.com/Pages/Response…

English

1

45

Center for U.S. Policy@USPolicyCenter·1 Şub

In response to an activist group opposing FDA funding for a substance misuse surveillance program, CUSP sent FDA a letter underscoring RADARS System's role in researching and responding to medication diversion, substance misuse, and addiction. Read letter: centerforuspolicy.org/cusp-letter-to…

English

55

Center for U.S. Policy@USPolicyCenter·26 Ara

Thank you @GovKathyHochul for signing S2677/A463 to help ensure patients get the information they need when faced with a denial due to #steptherapy. Thank you @NeilBreslin46 and @johnmcdonald108 for your leadership! #HappyHolidays

English

1

58

Center for U.S. Policy@USPolicyCenter·7 Kas

The Journal of Opioid Management has published a special edition, edited by our Chairman @MCBtweets and featuring our Senior Fellow @LynnRWebsterMD. It explores legal and policy responses to improper #pain management and #opioid misuse. Learn more: finance.yahoo.com/news/journal-p…

English

58

Center for U.S. Policy@USPolicyCenter·19 Eyl

Considering a career in addiction policy? Tune into the virtual info session on the M.S. in Addiction Policy and Practice program at Georgetown University's Graduate School of Arts & Sciences on Sept. 25 at noon hosted by @ReginaLabelle. Register here: gradapply.georgetown.edu/register/?id=b…

English

1

54

Center for U.S. Policy@USPolicyCenter·8 Ağu

.@InHealthPolicy reported FDA’s denial of CUSP’s Citizen Petition to classify risk assessment software a misbranded medical device and enforce a recall. Procedural grounds cited, but FDA will evaluate the matter for potential further actions. Learn more: insidehealthpolicy.com/daily-news/fda…

English

2

3

106

Center for U.S. Policy@USPolicyCenter·8 Ağu

On July 28, 2023, @US_FDA approved the second OTC #naloxone product, helping increase consumer access to naloxone without a prescription. It is anticipated to be available early 2024 to #harmreduction organizations and state governments. Learn more here: fda.gov/news-events/pr…

English

An effort to get the FDA to pull a widely used prescription drug monitoring software package off the market is stoking a broader debate over how much technology is influencing opioid prescribing. trib.al/5PWlJxa

1

38

Center for U.S. Policy@USPolicyCenter·1 Ağu

The @US_FDA denied the Citizen Petition by CUSP to deem a #SUD risk-scoring clinical decision support software a misbranded medical device. Despite the decision being procedural, the health and safety concerns raised remain significant. Learn more here: finance.yahoo.com/news/fda-denie…

English

2

91

Center for U.S. Policy@USPolicyCenter·26 May

Thanks, @axios, for covering our citizen petition to protect people with #pain and others who need controlled medications. We appreciate your objectivity.

Axios@axios

English

1

45

Center for U.S. Policy@USPolicyCenter·17 May

A more direct, efficient approach to enhancing access to #methadone for #OUD is to reduce regulatory burdens and delays hindering the establishment of OTP medication units in pharmacies. finance.yahoo.com/news/health-po…

English

3

4

6

877

Center for U.S. Policy@USPolicyCenter·30 Nis

@mguptaphd @aander1987 @jenndoliva Given a lack of transparency as to which programs are used in health care, which data they analyze, and how they analyze it, we do not know.

English

1

14

MGupta PhD (she/her) 🌻🦓@mguptaphd·29 Nis

@aander1987 @USPolicyCenter @jenndoliva I was ironically put in a lock-in program last year because I was constantly being shuffled between doctors, with no one willing to oversee long-term (even non-opioid) pain med mgmt. Medicaid penalized me, but wouldn’t speak to any of my drs. 🙄 Is this the same algorithm?

English

0

1

25

Andrea Anderson@aander1987·29 Nis

Excellent work by @USPolicyCenter addressing the criminalization of medicine & the egregious patient harms that occur when pts are “scored” and denied care based on that score, but cannot know about, or appeal their scores. Thank you @jenndoliva for your work on this!

Today, we filed a Citizen Petition asking @US_FDA to deem software that creates patient “risk scores” a misbranded device and to take action to prevent serious, adverse health consequences and death. Read the petition here: centerforuspolicy.org/fdacp2023/ #OUD #pain #anxiety #insomnia

English

11

20

433

Center for U.S. Policy retweetledi

TwistedKat ♿️@KatTwisted·30 Nis

👏🏼👏🏼👏🏼👏🏼

Today, we filed a Citizen Petition asking @US_FDA to deem software that creates patient “risk scores” a misbranded device and to take action to prevent serious, adverse health consequences and death. Read the petition here: centerforuspolicy.org/fdacp2023/ #OUD #pain #anxiety #insomnia

ART

3

6

128

Center for U.S. Policy retweetledi

FanClub@HatingLiars·30 Nis

Excellent News! This is a very good thing.

Today, we filed a Citizen Petition asking @US_FDA to deem software that creates patient “risk scores” a misbranded device and to take action to prevent serious, adverse health consequences and death. Read the petition here: centerforuspolicy.org/fdacp2023/ #OUD #pain #anxiety #insomnia

English

2

48

Center for U.S. Policy retweetledi

Pain News Network@PainNewsNetwork·29 Nis

A citizen's petition to #FDA asks that #NarxCare be taken off the market. #NarxCare software analyzes drug data to give patients “risk scores,” but critics say its a misbranded medical device that harms patients. @BambooHLTH #cpp #opioids #chronicpain bit.ly/41IQvZI

English

9

17

502

Center for U.S. Policy retweetledi

Michael C. Barnes@MCBtweets·29 Nis

When patients have inadequate access to medically necessary controlled medications, the harms can include relegation to the illicit drug market, exposure to substances adulterated with illegal fentanyl, prosecution and incarceration, drug poisoning, suicide, and death.

Today, we filed a Citizen Petition asking @US_FDA to deem software that creates patient “risk scores” a misbranded device and to take action to prevent serious, adverse health consequences and death. Read the petition here: centerforuspolicy.org/fdacp2023/ #OUD #pain #anxiety #insomnia

English

2

7

16

716

Center for U.S. Policy@USPolicyCenter·29 Nis

Thank you for your courageous thought leadership and advocacy, @jenndoliva. 🙏

English

1

151

Center for U.S. Policy@USPolicyCenter·28 Nis

Today, we filed a Citizen Petition asking @US_FDA to deem software that creates patient “risk scores” a misbranded device and to take action to prevent serious, adverse health consequences and death. Read the petition here: centerforuspolicy.org/fdacp2023/ #OUD #pain #anxiety #insomnia

English

15

46

94

13.4K

Center for U.S. Policy retweetledi

Journal of Medical Regulation@JournalofMedReg·28 Nis

JMR is extending an open call for submissions in 2023! We welcome manuscripts spanning original research, best practices, commentaries about patient safety & related matters relevant to medical regulators in the U.S. & around the world. bit.ly/3Qrycmt #callforpapers

Journal of Medical Regulation tweet media

English

6

7

302

Center for U.S. Policy retweetledi

Journal of Medical Regulation@JournalofMedReg·30 Mar

ICYMI: “Demanding Better: A Case for Increased Funding & Involvement of State Medical Boards in Response to America’s Drug Abuse Crisis,” by authors from @dcbalaw & @USPolicyCenter: bit.ly/3oEAqjX

English